Helping life sciences leaders turn health policy shifts into clear commercial strategy for China.

Latest

Aug
13
▶️Frontline Perspectives: Realities and the Road Ahead for Commercial Health Insurance in China

▶️Frontline Perspectives: Realities and the Road Ahead for Commercial Health Insurance in China

Two senior commercial insurance leaders share candid views on China’s evolving market—what’s working, where integration lags, and if the new commercial innovative drug list could help close gaps and drive future growth.
2 min read
Aug
06
▶️Fudan’s Wanyan Ruiyun on Huiminbao and the C-List: From Central Negotiation to Market Uptake and Insurance Innovation

▶️Fudan’s Wanyan Ruiyun on Huiminbao and the C-List: From Central Negotiation to Market Uptake and Insurance Innovation

Fudan expert shares insights on China’s first national negotiation for the commercial drug list—and its potential to reshape Huiminbao, influence drug pricing, accelerate insurance innovation, and transform drug distribution systems nationwide.
2 min read
Jul
18
▶️Navigating China’s Multi-Level Coverage Framework: Insights from the C-List Strategy Panel

▶️Navigating China’s Multi-Level Coverage Framework: Insights from the C-List Strategy Panel

Industry leaders unpack China’s evolving multi-level coverage system—what the dual-list means for pricing risk, NRDL vs. commercial access, and long-term strategy in the C-List era.
1 min read
Jul
03
NHSA Moves Forward with China’s First Dual-List Adjustment for NRDL and Commercial Drug Catalog

NHSA Moves Forward with China’s First Dual-List Adjustment for NRDL and Commercial Drug Catalog

What will China’s new dual-list mechanism mean for launch timing, pricing risks, and long-term market potential for innovative drugs?
1 min read
Jun
20
NHSA Consults on 2025 Dual-List Adjustment Work Plan for NRDL and Commercial Drug List

NHSA Consults on 2025 Dual-List Adjustment Work Plan for NRDL and Commercial Drug List

The Dual-List Adjustment Mechanism marks a pivotal shift in China’s reimbursement system, prompting key strategic questions for innovative drug makers.
5 min read
Jun
11
▶️Connecting the Dots for Global Pharma: Critical Factors Driving Success in China

▶️Connecting the Dots for Global Pharma: Critical Factors Driving Success in China

This Q&A explores the growing gap between global pharma strategies and China’s payer priorities—offering a self-assessment tool for internal alignment, and insights into risks and opportunities in the commercial catalog pathway.
3 min read
May
08
Positioning for Success: Navigating China’s C-List and Commercial Catalog for Innovative Medicines

Positioning for Success: Navigating China’s C-List and Commercial Catalog for Innovative Medicines

Gain practical tools and insight to navigate China’s C-List and Commercial Catalog—and make informed decisions on product positioning across emerging access pathways.
2 min read
Apr
30
NRDL+ 2025 Annual Executive Debrief: The State of Access for Innovative Medicines in China

NRDL+ 2025 Annual Executive Debrief: The State of Access for Innovative Medicines in China

This Access360 Executive Briefing lays the groundwork for understanding China’s shift toward value-based pricing, deeper insurance–medicine–care integration, and broader market transformation driven by its national commercial insurance catalog initiatives.
1 min read
Apr
02
China’s Insurance Industry Moves to Standardize Drug Coverage: Draft Commercial A-List Now Open for Feedback

China’s Insurance Industry Moves to Standardize Drug Coverage: Draft Commercial A-List Now Open for Feedback

As NHSA pilots C-List reimbursement models, a parallel effort by the Insurance Association of China has produced its first national formulary draft—offering a framework that could define future specialty drug access under Huiminbao and beyond.
3 min read
Mar
05
China’s Commercial Insurance Catalog Accelerates Expanding Beyond Category C Drug List

China’s Commercial Insurance Catalog Accelerates Expanding Beyond Category C Drug List

Led by the Insurance Association of China, this initiative alongside the NHSA-led Category C Drug List, is reshaping funding pathways, pricing strategies, and market access for innovative medicines.
5 min read